Frail elderly patients with relapsed-refractory multiple myeloma: efficacy and toxicity profile of the combination of bortezomib, high-dose dexamethasone, and low-dose oral cyclophosphamide

被引：12
|
作者：
Mele, Giuseppe [1 ]
Giannotta, Angela
Pinna, Salvatore
Loseto, Giacomo
Coppi, Maria Rosaria
Brocca, Claudio Maurizio
Melpignano, Angela
Quarta, Giovanni
机构：
[1] Antonio Perrino Hosp, Clin Div Hematol, I-72100 Brindisi, Italy
来源：
LEUKEMIA & LYMPHOMA | 2010年 / 51卷 / 05期
关键词：
PREDNISONE PLUS THALIDOMIDE; MELPHALAN;
D O I：
10.3109/10428191003695660
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：937 / 940
页数：4
相关论文
共 50 条
  • [21] LENALIDOMIDE PLUS HIGH-DOSE VERSUS LOW-DOSE DEXAMETHASONE FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA: A SYSTEMATIC REVIEW
    Kupas, K.
    Kaspar, I.
    Baecke, V.
    Weisel, K.
    HAEMATOLOGICA, 2017, 102 : 514 - 515
  • [22] Bendamustine, Bortezomib and Dexamethasone (BVD): A Combination With a Substantial Activity and a Manageable Toxicity In Patients With Relapsed-Refractory Multiple Myeloma (MM)
    Offidani, Massimo
    Corvatta, Laura
    Maracci, Laura
    Liberati, Anna Marina
    Ballanti, Stelvio
    Attolico, Immacolata
    Caraffa, Patrizia
    Alesiani, Francesco
    di Toritto, Tommaso Caravita
    Gentili, Silvia
    Tosi, Patrizia
    Brunori, Marino
    Derudas, Daniele
    Ledda, Antonio
    Gozzetti, Alessandro
    Cellini, Claudia
    Malerba, Lara
    Mele, Anna
    Andriani, Alessandro
    Galimberti, Sara
    Mondello, Patrizia
    Pulini, Stefano
    Coppetelli, Ugo
    Fraticelli, Paolo
    Olivieri, Attilio
    Leoni, Pietro
    BLOOD, 2013, 122 (21)
  • [23] Phase 2 study of all-oral ixazomib, cyclophosphamide and low-dose dexamethasone for relapsed/refractory multiple myeloma
    Kumar, Shaji K.
    Grzasko, Norbert
    Delimpasi, Sosana
    Jedrzejczak, Wieslaw W.
    Grosicki, Sebastian
    Kyrtsonis, Marie-Christine
    Spencer, Andrew
    Gupta, Neeraj
    Teng, Zhaoyang
    Byrne, Catriona
    Labotka, Richard
    Dimopoulos, Meletios A.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 184 (04) : 536 - 546
  • [24] Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma
    Badros, Ashraf
    Hyjek, Elizabeth
    Ma, Ning
    Lesokhin, Alexander
    Dogan, Ahmet
    Rapoport, Aaron P.
    Kocoglu, Mehmet
    Lederer, Emily
    Philip, Sunita
    Milliron, Todd
    Dell, Cameron
    Goloubeva, Olga
    Singh, Zeba
    BLOOD, 2017, 130 (10) : 1189 - 1197
  • [25] Bortezomib and Low-Dose Dexamethasone with or without Continuous Low-Dose Oral Cyclophosphamide for Primary Refractory or Relapsed Multiple Myeloma: Final Results of a National Multicenter Randomized Controlled Phase III Study
    Kropff, Martin
    Vogel, Martin
    Kreter, Andrea
    Schlag, Rudolf
    Mueller, Lothar
    Weide, Rudolf
    Knauf, Wolfgang
    Decker, Thomas
    Fiechtner, Heinrich
    Kojouharoff, Georgi
    Kremers, Stephan
    Berdel, Wolfgang E.
    BLOOD, 2014, 124 (21)
  • [26] EFFICACY OF THE COMBINATION THERAPY OF LIPOSOMAL ADRYAMICIN, BORTEZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE (ABCD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS
    Romano, A.
    Chiarenza, A.
    Gorgone, A.
    Schinocca, L.
    Uccello, G.
    Cavalli, M.
    Fiumara, P.
    Motta, G.
    Palumbo, G.
    Di Raimondo, F.
    HAEMATOLOGICA, 2012, 97 : 607 - 607
  • [27] A Phase 2 Study of Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
    Lonial, Sagar
    Jakubowiak, Andrzej J.
    Jagannath, Sundar
    Raab, Marc S.
    Facon, Thierry
    Vij, Ravi
    Moreau, Philippe
    Reece, Donna E.
    White, Darrell J.
    Benboubker, Lotfi
    Zonder, Jeffrey A.
    Rossi, Jean-Francois
    Tsao, Claire
    Parli, Teresa
    Kroog, Glenn
    Singhal, Anil K.
    Richardson, Paul G.
    BLOOD, 2011, 118 (21) : 141 - 142
  • [28] Immune Profiling of Relapsed or Refractory Multiple Myeloma Patients Treated with Pomalidomide and Low-Dose Dexamethasone in Combination with Daratumumab
    Pierceall, William E.
    Bahlis, Nizar
    Siegel, David S.
    Schiller, Gary J.
    Samaras, Christy J.
    Sebag, Michael
    Berdeja, Jesus G.
    Ganguly, Siddhartha
    Matous, Jeffrey V.
    Song, Kevin
    Seet, Christopher S.
    Talamo, Giampaolo
    Srinivas, Shanti
    Acosta-Rivera, Mirelis
    Bar, Michael
    Quick, Donald P.
    Anz, Bertrand
    Fonseca, Gustavo
    Reece, Donna
    Chung, Weiyuan
    Serbina, Natalya
    Zafar, Faiza
    Agarwal, Amit
    Thakurta, Anjan
    BLOOD, 2018, 132
  • [29] BORTEZOMIB PLUS DEXAMETHASONE IN COMBINATION WITH MELPHALAN OR CYCLOPHOSPHAMIDE IN THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
    Tsirigotis, P.
    Girkas, K. G.
    Giannopoulou, V.
    Chondropoulos, S.
    Ioannidou, E.
    Papaxoinis, G.
    Pappa, V.
    Vasilatou, D.
    Dimoula, K.
    Kapodistrias, N.
    Papageorgiou, E.
    Economopoulos, T.
    Dervenoulas, J.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 436 - 436
  • [30] Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study
    M Offidani
    L Corvatta
    L Maracci
    A M Liberati
    S Ballanti
    I Attolico
    P Caraffa
    F Alesiani
    T Caravita di Toritto
    S Gentili
    P Tosi
    M Brunori
    D Derudas
    A Ledda
    A Gozzetti
    C Cellini
    L Malerba
    A Mele
    A Andriani
    S Galimberti
    P Mondello
    S Pulini
    U Coppetelli
    P Fraticelli
    A Olivieri
    P Leoni
    Blood Cancer Journal, 2013, 3 : e162 - e162
12345